Business Wire

Ant International President Highlights AI and Connectivity as Key SME Growth Drivers

12.3.2025 12:19:00 CET | Business Wire | Press release

Share

Artificial Intelligence (AI) is being converted into flexible cross-border payment and digitisation solutions to help SMEs raise efficiency, lowering costs and controlling risks.More industry collaborations are needed to bridge payment systems and tech know-how.

Digital payment innovations are increasingly powerful tools for global businesses to raise productivity and turbocharge growth. The Digital Payment Market size1 is expected to grow at a CAGR of 11.8% and reach US$193.7 billion. However, there are digital divides and silos abound in core financial services for the global commerce system, especially in cross-border online and offline digital payment and settlement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312187829/en/

Douglas Feagin (left), President of Ant International, discussed payments innovation at GFTN Forum Japan in March 2025. (Photo: Business Wire)

“Even as technology advances in leaps and bounds, small businesses continue to face challenges in today’s digitised international transactions, from cross-border payment to cross-market growth,” said Douglas Feagin, President of Ant International, during the GFTN Forum held during the Japan Fintech Festival in Japan in March 2025. “We need to convert exciting developments in foundational technologies, such as AI, into comprehensive, effective and affordable solutions for the world’s long-tail business community.”

Ant International’s flagship Alipay+ cross-border mobile payment and digitisation technology has expanded to support 36 international payment apps, connecting over 90 million merchants across 66 markets. This “invisible” technology behind the cash register enables merchants to receive cross-border payments seamlessly and securely from individuals using their home e-wallets while maintaining competitive foreign exchange rates.

Interoperability is key, as local SMEs should be able to accept international payments more easily. In Asia, initiatives like national QRs have greatly boosted connectivity, and Alipay+ helps to bridge these infrastructures with our global payment partner users, but more needs to be done to bring together card and wallet-based ecosystems, Feagin said.

For SMEs, the capacity to accept various forms of international payments is not merely an advantage; it has become an essential factor for survival and growth in an increasingly competitive marketplace, Feagin noted.

Artificial Intelligence (AI) technology is crucial in addressing these pressing needs by providing tools that help SMEs make informed decisions swiftly, ensuring they meet customer demands while minimizing operational risks. A recent McKinsey report2 for 2025 underscores this importance, indicating that 92% of businesses plan to increase their AI investments this year. The consulting firm earlier predicted that companies integrating AI into their financial operations can expect productivity increases of up to 25%3.

At Ant International, AI-powered solutions are being developed to forecast currency demands based on transaction flows, enhancing efficiency in foreign exchange processes and steering the industry towards real-time payment systems.

For instance, Ant International’s AI-driven solution can forecast customers’ foreign-exchange needs with more than 90% accuracy based on provided data, which enables the company to help customers optimise their FX strategies.

As financial fraud becomes increasingly sophisticated, AI is paramount in safeguarding transactions. Ant International’s AI-powered risk management capabilities can effectively implement advanced fraud detection mechanisms that analyse patterns, identify anomalies, and protect against potential threats.

Interoperability will continue to be enhanced, particularly in Asia, where national QR systems and mobile wallets facilitate seamless transactions. This trend is expected to evolve rapidly as new LLM models are developed, enabling companies to streamline these workflows, said Feagin.

“We expect this revolution to continue at a rapid pace, and AI to accelerate efficiency and provide solutions for our customers,” added Feagin.

1https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html
2https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/superagency-in-the-workplace-empowering-people-to-unlock-ais-full-potential-at-work
3https://psico-smart.com/en/blogs/blog-how-can-artificial-intelligence-enhance-productivity-management-in-the-workplace-88579

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312187829/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye